Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT00846742
PHASE2

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma

Sponsor: St. Jude Children's Research Hospital

View on ClinicalTrials.gov

Summary

This phase II trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with favorable-risk Hodgkin lymphoma. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, mechlorethamine hydrochloride, vincristine sulfate, bleomycin, etoposide, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high-energy x-rays to kill cancer cells for those patients that still had residual cancer at the end of chemotherapy. Giving combination chemotherapy with radiation therapy may kill more cancer cells and allow doctors to save the part of the body where the cancer started.

Official title: Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy For Favorable Risk Pediatric Hodgkin Lymphoma

Key Details

Gender

All

Age Range

Any - 21 Years

Study Type

INTERVENTIONAL

Enrollment

88

Start Date

2009-06-05

Completion Date

2028-10

Last Updated

2025-12-08

Healthy Volunteers

No

Interventions

DRUG

Stanford V Chemotherapy

The Stanford V regimen is an abbreviated, multi-agent, dose-intensive regimen that utilizes many of the most active chemotherapy agents for Hodgkin lymphoma: Vinblastine, Doxorubicin, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone

RADIATION

Radiation Therapy

Patients who achieve less than a complete response after 8 weeks of chemotherapy will receive 25.5 Gy to individual nodal sites (tailored fields) starting 2-3 weeks following completion of all chemotherapy and recovery of ANC to at least 1000.

Locations (6)

Packard Children's Hospital, Stanford University

Palo Alto, California, United States

Rady Children's Hospital- San Diego

San Diego, California, United States

Children's Hospital of Illinois at OSF St. Francis Medical Center

Peoria, Illinois, United States

Maine Children's Cancer Program (MCCP)

Scarborough, Maine, United States

Dana-Farber Harvard Cancer Center

Boston, Massachusetts, United States

St. Jude Children's Research Hospital

Memphis, Tennessee, United States